Clinical use of Bevacizumab in treating refractory glaucoma

Popescu V et al.
2015
Issue 1
pp 8 - 12

Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab...

View Article Download PDF